Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin add-on to metformin plus PPAR-gamma agonist in inadequately controlled type 2 diabetes
2006-002488-20Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin add-on with Placebo add-on (2 arms). Primary endpoints: Change in HbA1c at 18 weeks and Safety and tolerability of sitagliptin. Started Jul 2007; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-002488-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002488-20.